Cited by 90Circadian rhythm and melatoninAutism Spectrum Disorder ResearchSleep and related disorders

Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder

Open access
Lalanne, Sébastien, Fougerou-Leurent, Claire, Anderson, George M., Schroder, Carmen M., Nir, Tali, Chokron, Sylvie, Delorme, Richard, Claustrat, Bruno +5 more·2021·International Journal of Molecular Sciences

Abstract

The role of melatonin has been extensively investigated in pathophysiological conditions, including autism spectrum disorder (ASD). Reduced melatonin secretion has been reported in ASD and led to many clinical trials using immediate-release and prolonged-release oral formulations of melatonin. However, melatonin's effects in ASD and the choice of formulation type require further study. Therapeutic benefits of melatonin on sleep disorders in ASD were observed, notably on sleep latency and sleep quality. Importantly, melatonin may also have a role in improving autistic behavioral impairments. The objective of this article is to review factors influencing treatment response and possible side effects following melatonin administration. It appears that the effects of exposure to exogenous melatonin are dependent on age, sex, route and time of administration, formulation type, dose, and association with several substances (such as tobacco or contraceptive pills). In addition, no major melatonin-related adverse effect was described in typical development and ASD. In conclusion, melatonin represents currently a well-validated and tolerated treatment for sleep disorders in children and adolescents with ASD. A more thorough consideration of factors influencing melatonin pharmacokinetics could illuminate the best use of melatonin in this population. Future studies are required in ASD to explore further dose-effect relationships of melatonin on sleep problems and autistic behavioral impairments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22031490

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 111 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Lalanne, S., Fougerou-Leurent, C., Anderson, G. M., Schroder, C. M., Nir, T., Chokron, S., Delorme, R., Claustrat, B., Bellissant, E., Kermarrec, S., Franco, P., Denis, L., & Tordjman, S.
Affiliations
  • Inserm (FR)
  • Experimental and Clinical Pharmacology Department, CHU Rennes, 35033 Rennes, France
  • Yale University (US)
  • Centre National de la Recherche Scientifique (FR)
  • Neurim Pharmaceuticals (Israel) (IL)
  • Integrative Neuroscience and Cognition Center (INCC), CNRS UMR 8002 and University of Paris, 75006 Paris, France
  • Université Paris Cité (FR)
  • Centre Hospitalier Guillaume Régnier (FR)
  • Lyon 1 Université (FR)
Corresponding author
  • Lalanne, Sébastien
  • Tordjman, Sylvie
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-02-02
Volume
22
Issue
3
Pages
1490
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3127752314
Cited by
90
References
111
Citations by year
2026: 11 · 2025: 17 · 2024: 19 · 2023: 19 · 2022: 17 · 2021: 7
FWCI
1.98
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
melatonin, autism spectrum disorder, sleep disorders, sleep latency, sleep quality, treatment response, adverse effects, dose-response relationship, children and adolescents
MeSH terms
Autism Spectrum Disorder, Sleep Latency, Administration, Oral, Adult, Biological Availability, Child, Child, Preschool, Circadian Rhythm, Delayed-Action Preparations, Female, Humans, Injections, Intravenous, Male, Melatonin, Saliva, Seasons, Serotonin, Social Behavior Disorders, Tryptophan, Dietary Supplements, Sleep Disorders, Intrinsic, Receptors, Melatonin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review